NCT01697956View on ClinicalTrials.gov

Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR)

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions

Allergic Rhinitis

Interventions

DRUG

BDP

Beclomethasone dipropionate (BDP) 80 mcg/day (40 mcg/spray, 1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.

DRUG

Placebo

Placebo (1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.

Trial Locations (6)

Unknown

Teva Investigational Site 10305, Long Beach

Teva Investigational Site 10304, Stockbridge

Teva Investigational Site 10300, Plymouth

Teva Investigational Site 10302, Normal Square

Teva Investigational Site 10301, New Braunfels

Teva Investigational Site 10303, San Antonio

All Listed Sponsors

lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

NCT01697956 - Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR) | Biotech Hunter | Biotech Hunter